Shareholder Information

SkinBioTherapeutics plc is listed on the Alternative Investment Market (AIM) of the London Stock Exchange. The Company has not applied or agreed to have any of it securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.

Issued share capital: 190,850,600 Ordinary Shares of 1p nominal value.

The percentage of Ordinary Shares not being held in public hands is 21.2%.
Shares held in treasury: Nil Ordinary shares.
There are no restrictions on the transfer of Ordinary Shares in the Company.

As an AIM traded UK registered company, SkinBioTherapeutics plc is subject to the UK City Code on Takeovers and Mergers legislation.

Detailed Share Price

Symbol Last Ask Change (%) Bid Change (%) Ask Bid Ask Volume Bid Volume High

Significant Shareholders
As at 30th November 2023 significant shareholders that hold more than 3% of the share capital of SkinBioTherapeutics plc are detailed below:


Number Ordinary Shares %
OptiBiotix Health Plc 25,740,639 13.52%
Seneca Partners Limited 14,563,399 7.65%
Tyndall Investment Management 13,822,799 7.26%
The University of Manchester 8,000,000 4.20%
Unicorn Asset Management 7,894,737 4.15%

Director Shareholders

Number Ordinary Shares %
Martin Hunt* 560,417 0.29%
Stuart John Ashman 276,804 0.15%
Manprit Randhawa 153,165 0.08%
Dr Cathy Prescott 181,112 0.10%
Danielle Bekker 43,750 0.02%

*Martin Hunt’s shareholding is held through Invictus Management Limited, a company controlled by Mr Hunt. Of the 560,417 shares held by Invictus Management Limited 11,112 are held on behalf of Louise Hunt and 11,111 are held on behalf of Oliver Hunt.